Related Experiment Videos
Magnetic resonance contrast agents for neuroimaging. Safety issues
1Department of Radiology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Neuroimaging Clinics of North America
|February 1, 1994
Summary
Magnetopharmaceuticals, like gadopentetate dimeglumine, are generally safe for patient diagnostics, with most adverse events being minor. Severe reactions are rare but possible, necessitating preparedness for potential complications.
Area of Science:
- Radiology and Medical Imaging
- Pharmacovigilance
- Patient Safety
Background:
- Physicians must balance diagnostic benefits of magnetopharmaceuticals against potential risks.
- Current FDA-approved magnetopharmaceuticals exhibit a good overall safety profile regarding acute toxicity.
- Gadopentetate dimeglumine, with extensive clinical use, shows a high incidence of transient, minor adverse events.
Observation:
- Newer magnetopharmaceutical agents demonstrate similar safety profiles in clinical trials, albeit with less extensive data.
- Severe, idiosyncratic, anaphylactoid reactions, though infrequent, can lead to permanent injury or death.
- Patients with a history of reactive airway disease may be at higher risk for severe reactions.
Findings:
- The estimated incidence of severe reactions for gadopentetate dimeglumine is 1 in 350,000 to 450,000, significantly lower than iodinated contrast agents.
- Magnetopharmaceuticals are considered safe but not without risk, requiring careful consideration of benefits versus potential harm.
- Post-marketing surveillance is crucial for ongoing safety monitoring and information gathering.
Implications:
- Radiologists must be prepared for rare severe adverse events with appropriate equipment and trained personnel.
- The diagnostic advantages of magnetopharmaceuticals, leading to reduced morbidity and mortality, justify their continued use and development.
- Informed patient consent regarding the small risks associated with magnetopharmaceuticals is essential.